Publication - 2017A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Publication

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Simvastatin inhibits interferon-γ signaling by blocking activation of STAT and prevented and reversed disease in our mouse model. We conducted a small, randomized, double-blind, placebo-controlled, phase II clinical trial to test simvastatin as a treatment for vitiligo. Our study does not support the use of oral simvastatin for the treatment of vitiligo. Disparate findings in this study compared with our mouse model may be a result of dosing limitations in human beings because of potential toxicity, which is not a concern in mice.

Full text   

Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE



FAQOther Questions

  • Shall I try low-fat diet for my vitiligo?

    The link between dietary fat and autoimmune diseases like vitiligo is a compelling yet complex puzzle that continues to intrigue scientists. While the conversation is ongoing, o...

  • How smoking affects vitiligo?

    Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....

  • How can I cure vitiligo?

    Right now, there is no universal "cure," but we have entered a new era of treatment. Today, managing vitiligo isn’t just about "hiding" it; it’s about sophisticated science that...